TP53 and myeloid sarcoma: We compared the occurrence of various genomic events between two MS cohorts using the chi‐squared test (Supporting Information: Table S5), and observed a higher rate of CTNNB1 and TP53 mutations, as well as amplification of 14q11.2, loss of 22q12.1, and loss of 9p21.3 in MS1 with a worse prognosis (Figure 5A, Supporting Information: Figure S13).